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Elevated antibody responses toMycobacterium tuberculosis antigens in individuals with latent infection (LTBI) have previously been
linked to an increased risk for progression to active disease. Studies in the field focussed mainly on IgG antibodies. In the present
study, IgA and/or IgG responses to the mycobacterial protein antigens AlaDH, NarL, 19 kDa, PstS3, and MPT83 were determined
in a blinded fashion in sera from 53 LTBI controls, 14 healthy controls, and 42 active TB subjects. Among controls, we found that
elevated IgA levels against all investigated antigens were not randomly distributed but concentrated on a subgroup of < 30%—with
particular high levels in a small subgroup of∼ 5% comprising one progressor to active TB. Based on a specificity of 100%, anti-NarL
IgA antibodies achieved with 78.6% sensitivity the highest accuracy for the detection of active TB compared to healthy controls.
In conclusion, the consistently elevated IgA levels in a subgroup of controls suggest higher mycobacterial load, a risk factor for
progression to active TB, and together with high IgG levels may have prognostic potential and should be investigated in future
large scale studies. The novel antigen NarL may also be promising for the antibody-based diagnosis of active TB cases.
1. Introduction
Approximately one third of the world’s population has
latent infection with Mycobacterium tuberculosis [1]. Latent
M. tuberculosis infection (LTBI) represents a considerable
reservoir of future active disease and contagion. Risk factors
include co-infection with human immunodeficiency virus
(HIV), diabetes mellitus, low body weight, old age, or use
of immunosuppressive medications. In immunocompetent
individuals, the annual risk of progression is estimated to be
greatest in the first 1 or 2 years after infection.
Preventing LTBI individuals from reactivation (before
they become symptomatic and infectious) may constitute a
major step towards the elimination of TB. Therefore, the
revised global plan to stop TB (2011–15) [2] has set 2015 as the
goal for point-of-care tests that can be used for the accurate
detection of preclinical TB.
Bacterial load is associatedwith disease risk, and antibody
levels againstM. tuberculosis components may be biomarkers
for load [3] as well as disease risk [4–6]. Stratification of
TB suspects into groups of absent, low (smear-negative
tuberculosis), and high (smear-positive tuberculosis) bac-
terial burden showed that antibody levels correlated with
bacillary burden [4]. In the same study, data of the macaque
model, which reproduces key features of latent TB in humans,
showed that infection outcome was reflected by the antibody
response in the latent infection group [4], thereby confirming
previous animal studies [7–9]. Although studies were small,
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increased specific antibody levels during the LTBI stage in
humans also characterized progressors [5, 6]. Antibody-
based tests for the diagnosis of active TB disease are often
criticized for their lack of specificity in TB endemic regions
[10], which is due to a high background prevalence of LTBI
[11]. Clearly, further research is needed to elucidate whether
M. tuberculosis specific antibody tests can determine active
TB and cases at risk for progression and whether lack of
specificity of antibody-based TB tests will turn out to be due
to a high risk for an early stage of progression to active TB.
The low frequency of reactivation in immunocompe-
tent LTBI individuals poses a challenge for the discovery
of prognostic markers. Therefore, we chose to investigate
the distribution of serologic responses, as a nonrandom
distribution may point to a subgroup with higher bacterial
load and an increased risk for future progression to disease.
In a South African TB endemic population, we evaluated
the serodiagnostic reactivity of L-alanine dehydrogenase
(AlaDH) (Rv2780), nitrate/nitrite response transcriptional
regulator NarL (Rv0844c), periplasmic phosphate-binding
lipoprotein PstS3 (Rv0928), 19 kDa lipoprotein antigen pre-
cursor LpqH (Rv3763), and lipoprotein MPT83 (Rv2873).
IgG responses to each of the two surface-exposed lipopro-
teins, 19 kDa and MPT83, are predominantly recognized in
active TB sera and not in non-TB disease (NTBD) sera
[4]. The 19 kDa antigen promotes binding to host cells and
phagocytosis of mycobacteria [12], inhibits IFN-𝛾-induced
killing of mycobacteria by macrophages [13], and induces
macrophage apoptosis [14]. MPT83 elicits T cell proliferation
of the majority of TB patients and is being considered as
future subunit vaccine candidate [15]. The third lipoprotein,
M. tuberculosis PstS3, which is involved in active transport of
inorganic phosphate across the membrane (import), has not
been investigated yet in subjects with LTBI for the serodiag-
nosis of M. tuberculosis [16]. However, PstS3 generates IFN-
𝛾-producing cells in a more potent manner than the closely
related 38 kDa (PstS1) [17], a majorM. tuberculosis antigen [4,
18, 19]. The in TB serodiagnostics newly investigated protein
antigen NarL is a putative nitrate response regulator involved
in the regulation of anaerobic metabolism [20] and is part of
the membrane fraction ofM. tuberculosis [21]. IgG responses
to the culture filtrate (and membrane) protein AlaDH are
unable to distinguish untreated TB patients and controls in
endemic settings [22]. AlaDH is present inM. tuberculosis but
not in the vaccine strain Mycobacterium bovis BCG [21, 23].
It may play a role in cell wall synthesis as L-alanine is an
important constituent of the peptidoglycan layer.
We focused on IgA antibodies because M. tuberculo-
sis-specific IgA antibodies discriminated better than IgG
antibodies between active TB and TB endemic controls in
Africa [24] as well as between healthy close contacts of
pulmonary TB patients and healthy individuals without such
contact [25]. Moreover, IgA production was reported to be
highly T-cell dependent [26], and a protective role for IgA
was suggested in several murine models of mycobacterial
infection, for example, [27].
2. Materials and Methods
2.1. Study Population. Sera utilized to probe antibody assays
were from a retrospective serum bank collected from indi-
viduals in an epidemiological field site in metropolitan Cape
Town in South Africa with a population of whom 99.7%
are of mixed race. The incidence of new smear-positive TB
in this community was 341/100 000 population in 2002 and
the majority of people harbours latent infection [28]. In
the study community, BCG vaccination (Danish strain, 1331,
Statens Serum Institute, Copenhagen, Denmark) is routinely
administered at birth since 1971. The study was approved by
the Ethics Committee of the Faculty of Health Sciences at the
Stellenbosch University and written informed consent was
obtained from all participants or their legal guardians in the
case of children.
Community Control Subjects. Inclusion criteria for all healthy
control participants enrolled into the study were residence in
the described community, absence of clinical signs of TB or
other diseases, absence of prior TB, HIV negativity, and no
pregnancy. Several parameters were employed to determine
TB infection status: the Mantoux skin test, two different and
independent commercial interferon-𝛾 release assays (IGRAs)
[the QuantiFERONTBGold in Tube (QFT) (Qiagen, Hilden,
Germany, Australia) and T-SPOT.TB (Oxford Immunotec,
Abingdon, UK)], chest X-ray (CXR), and sputum AFB stain-
ing. We used >15mm as cut off for Mantoux test positivity
[29] and alternatively >5mm [30] as described in more
detail in the results section. Two IGRAs were used, as rates
of positive results have been reported to differ between T-
SPOT.TB and QuantiFERON-TB Gold (e.g. [31, 32]). Sixty-
four consecutively recruited recent household contacts of
active TB patients were part of a larger household contact
study, and because the non-LTBI individuals constituted
fewer than 20% of the contacts, three additional community
controls with no known previous TB exposure were added
and underwent the same investigations as the household
contacts except the IGRA assays. The majority of LTBI
subjects were followed up for the development of active
TB disease within 2 years after their first recruitment, and
one progressor (after 3 months) was identified according to
hospital records.
TB Patients. Forty-two HIV-negative, Ziehl-Neelsen sputum
smear-positive and BACTEC sputum culture-positive active
pulmonary TB patients with no known multidrug resistance
that were part of the same larger study as the controls, of
which results have been published recently [33, 34], were
included. Seven TB patients were excluded due to HIV-
seropositivity (𝑛 = 1), NTM infection (𝑛 = 2), or
concomitant illness, such as diabetes mellitus (𝑛 = 4). All TB
patients were self-reporting, untreated cases, and all except 2
had a first episode of active TB.
2.2. Serum Preparation. Blood samples of control subjects
and TB patients (at diagnosis prior to initiation of treatment)
were taken. After transport of the blood samples to the labo-
ratory (within 2 h of collection and at ambient conditions),
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Table 1: Recombinant antigens ofM. tuberculosis used in this study.
Protein name(s) Rv number Mol mass (kDa) Expression vector 6-fold His-Tag E. coli host strain
NarL Rv0844c 23.9 pET22 N-terminal BL21 (DE3)
AlaDH Rv2780 38.7 pJLA604 — CAG629
19 kDa glycolipoprotein, LpqH Rv3763 16.0 pET26 C-terminal BL21 (DE3)
PstS3 Rv0928 38.8 pET22 C-terminal Rosetta (DE3)
MPT83, MPB83 Rv2873 24.9 pET21 C-terminal BL21 (DE3) [pLysS]
Nitrate/nitrite response transcriptional regulatory protein NarL; secreted L-alanine dehydrogenase (AlaDH); 19 kDa lipoprotein antigen precursor LpqH;
periplasmic phosphate-binding lipoprotein PstS3; cell surface lipoprotein MPT83.
serum was separated by centrifugation (1250×g for 7min)
and stored in aliquots at −80∘C until use.
2.3. Antigen Cloning, Protein Expression, and Purifica-
tion. The production of the functional M. tuberculosis L-
alanine dehydrogenase (AlaDH) in the heat-induced strain
Escherichia (E.) coli CAG629 (pMSK12) has been described
previously [35]. For cloning, the genes of the remaining
4 protein antigens (Table 1) were amplified by PCR using
primers with integrated restriction sites allowing the site-
directed insertion of cleaved PCR-products into pET vectors
(Novagen). All four genes were fused to sequence coding
for 6-fold His-tag (Table 1). The genes were expressed in E.
coli BL21(DE3) or in case of pstS3 in E. coli Rosetta (DE3).
The antigens were purified using standard chromatographic
methods (affinity chromatography, ion exchange chromatog-
raphy, size exclusion chromatography). Insoluble antigens
were solubilized (refolded) from denaturating conditions
(8M urea) into buffers free of choatropic reagents. Further
details regarding the protein purification are described in the
supplements (see Supplementary Material available online at
http://dx.doi.org/10.1155/2015/364758).
2.4. Enzyme-Linked Immunosorbent Assay. Microtiter plates
were coated with M. tuberculosis antigens and serologic
antibody responses were determined using standard proce-
dures as described in the supplements. Laboratory personnel
performing the serodiagnosis assays were blinded to the
clinical status of the patients or the controls. Subsequent
record reviews were done by clinical staff to classify the
individuals into clinical groups without knowledge of the
serologic response phenotype.
2.5. Statistical Analysis. GraphPad Prism (Graph Pad, San
Diego, CA, USA) was used to create graphs and statistical
analyses were performed using Medcalc software (Kagi,
Berkeley, CA). The 𝑡-test for independent samples or the
Mann-Whitney test was used for the statistical comparison
of 2 groups depending on the fact whether or not the
data were normally distributed. Given the aim to develop
a diagnostic test for TB with a specificity level above at
least 90%, the experiments were analyzed by using specificity
levels of ≥ 90%, as was done by other investigators [36, 37].
The Spearman rank test was used for correlation analyses.
Generally, a two-tailed 𝑃 value of 𝑃 ≤ 0.05 was considered
significant.
3. Results
3.1. Classification of Study Participants according toTheirMyc-
obacterium tuberculosis Infection Status. Sixty-four healthy
household contacts of recently (within past 2 months) diag-
nosed active pulmonary TB patients underwent TST and 2
commercial IGRA tests, QFT, and T-SPOT.TB. Fifty-three
household contacts were classified as LTBI due to positivity
in TST (induration ≥ 15mm) [29], QFT and/or T-SPOT.TB
(𝑛 = 53; age range: 15–59 years; 58.2% females). The
remaining 11 household contacts were classified as healthy
controls (HC). As noninfected control individuals were rare
in the described TB endemic settings [28], we added 3
healthy nonhousehold contacts (community controls with
no known previous TB exposure) with TST-indurations
of 0mm, normal chest X-rays and AFB-negative-assisted
sputum samples to the healthy control group in order to
increase the statistical power (𝑛 = 14; age range: 10.7–
55.2 years; 71.4% females). The Mantoux induration > 15mm
criterion was used for the definition of LTBI, as a large-scale
study performed in a rural African population showed that
the local environmental mycobacterial exposure is reflected
in Mantoux indurations that cluster around 10mm, whereas
the M. tuberculosis exposures are reflected by indurations
with a mode at 15–17mm or larger [29]. Still, the exact
definition of the LTBI status is hampered by the lack of a
gold standard. According to Centers for Disease Control and
Prevention (CDC) criteria Mantoux induration > 5mm of
recent TB household contacts can be considered as LTBI [30],
and we alternatively considered this cut off for defining a
positive tuberculin reaction: of the fourteen members of the
original HC group, two subjects had Mantoux indurations
between 5mm and 15mm, and both individuals had negative
IGRA results. Therefore, in an alternative grouping of the
controls, we transferred the 2 IGRA-negative individuals with
Mantoux indurations between 5 and 15mm from the HC
group (HC∗: 𝑛 = 12) into the LTBI group (LTBI∗: 𝑛 = 55).
The 42 smear-positive active pulmonary TB patients (age
range: 18–55 years; 40.5% females) included in this study
were recruited from the same community as the control
participants.
3.2. Profile of Specific IgA and/or IgGAntibodies in an Endemic
Setting. The 5 protein antigens NarL, AlaDH, 19 kDa, PstS3,
and MPT83 (Table 1) were cloned and expressed in E. coli
and purified using standard chromatographic methods. A
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Figure 1: Quality control SDS-PAGE analysis (reduced) of the
highly purified recombinant antigens (1 𝜇g per lane). Lane 1: PstS3,
Lane 3: AlaDH, Lane 5: MPT83, Lane 7: 19 kDa, Lane 9: NarL, Lanes
2, 4, 6, 8, and 10: molecular weight ladders (each corresponding to
the antigen on the left side), Lanes 1–4: 15% Laemmli gels, and Lanes
5–10: 12% Laemmli gels. All stained with Coomassie brilliant blue
R250.
Coomassie Brilliant Blue R-250 stained SDS-PAGE analysis
of the 5 proteins is shown in Figure 1.
The 109 serum samples derived from 42 pulmonary
TB patients, 53 LTBI controls, and 14 non-LTBI controls
were tested in a blinded fashion for IgA responses specific
to the 5 proteins as well as for IgG responses to AlaDH.
Among controls, we found that elevated IgA levels against
the investigated 5 antigens were not randomly distributed
but concentrated on a subgroup of 28.4% (𝑛 = 19)—with
particular high levels in a subgroup of 4.5% (𝑛 = 3),
which comprised the progressor from latent infection to
active TB. To graphically distinguish between those LTBI
individuals with negative serum data (more than 70% of
the controls) and those with moderately elevated and highly
elevated serology, we used the mean ranks of IgA signals
against the 5 antigens investigated to divide the LTBI subjects
into the 3 subgroups LTBI (low IgA), LTBI (medium IgA)
and LTBI (high IgA) (Figure 2). Furthermore, we statistically
compared the non-LTBI controls with either the active TB
patients or the LTBI subgroup with elevated IgA signals
comprising the 2 subgroups LTBI (medium IgA) and LTBI
(high IgA) (Table 2). Based on a cut-off referring to the 92.9-
percentile of the healthy non-LTBI controls [92.9% (95%
CI, 66.1–99.8%) specificity], the IgA response against the
novel protein antigen NarL achieved with 81% (95%CI, 65.9–
91.4%) the highest sensitivity for the detection of active TB
patients, followed by anti-AlaDH IgA with 76.2% (95% CI,
60.5–87.9%) sensitivity and anti-19 kDa IgA with 64.3% (95%
CI, 48.0–78.4%) sensitivity (Table 2). Moreover, based on
a specificity of 100% (95% CI, 76.8–100%), anti-NarL IgA
and anti-AlaDH IgA both detected 84.2% (95% CI, 60.4–
96.6%) of the LTBI subgroup with elevated IgA signals,
followed by anti-19 kDa IgAwith 78.9% (95%CI, 54.4–93.9%)
sensitivity (Table 2). Anti-NarL IgA, anti-19 kDa IgA, and
anti-AlaDH IgA detected the LTBI (high IgA) subgroup,
which comprised the progressor to active TB, with a distinct
signal-to-noise ratio compared to the non-LTBI community
controls (Figures 2(a), 2(b), and 2(f)). In contrast, the LTBI
(high IgA) subgroup was indistinguishable from the non-
LTBI community controls when using the IgG response to
AlaDH (Figure 2(e)). Very similar results to those shown in
Table 2 were obtainedwhen using the alternative groupsHC∗
and LTBI∗ (Table S1).
When testing for correlations between the antibody OD
values in LTBI sera (𝑛 = 53) (Table 3 and Figure 3), we
found strong correlations between the IgA responses and
the 5 protein antigens [strongest correlation between anti-
AlaDH IgA and anti-19 kDa IgA: Spearman’s 𝑟 = 0.96 (95%
CI, 0.93–0.98); 𝑃 < 0.0001 (Figure 3(a)); weakest correlation
between anti-NarL IgA and anti-PstS3 IgA: 𝑟 = 0.82 (95%
CI, 0.71–0.89); 𝑃 < 0.0001 (Figure 3(d))]. In contrast, we
foundno or negligible correlations of any of the IgA responses
with the exemplarily tested IgG response to AlaDH [e.g., no
correlation between anti-AlaDH IgA and anti-AlaDH IgG:
𝑟 = 0.21 (95% CI, −0.06–0.46); 𝑃 = 0.128 (Figure 3(c))]
(Table 3). Very similar results to those shown in Table 3 were
obtained when using the alternative group LTBI∗ (Table S2).
4. Discussion
In recent years it became increasingly clear that antibody-
based diagnostics of active TB (often developed and tested in
non-TB endemic countries) performed poorly in TB endemic
settings [10] due to high background signals of antibodies
in LTBI individuals [11]. In our study we also found that
the presence of LTBI affected identification of active TB
by serology. In particular, we found that among controls
elevated IgA levels against the investigated 5 antigens were
not randomly distributed but concentrated on a subgroup
of <30%—with particular high levels in a small subgroup of
∼5%. The consistently elevated IgA levels in a subgroup of
controls suggest higher mycobacterial load, a risk factor for
progression to active TB.Whether high IgA and/or IgG levels
have prognostic potential should be investigated in future
large scale studies.
In several previous reports it has indeed been suggested,
directly or indirectly, that progression to active TB may be
predicted by increased specific antibodies levels. Certain TB-
specific antibody responses decline significantly during suc-
cessful therapy (and the time thereafter) when both bacterial
load and risk of disease also decline [38, 39]. In inactive TB
(defined by a positive response to the TST, negative sputum
cultures, and abnormal but stable CXR findings), a special
form of latent infection known to have increased risk of active
TB, elevated specific antibody responses have been reported
[40, 41]. Several independent studies showed that antibody
responses to mycobacterial proteins were detectable months
to years prior to the diagnosis of TB in persons infected
with HIV, for example, [8], again suggesting that in vivo M.
tuberculosis replication may begin long before progression to
active TB becomes clinically detectable. Specific antibacterial
antibodies have been shown to be present in sera obtained
from M. tuberculosis H37Rv aerosol-infected rabbits, and
guinea pigs both with preclinical TB [7, 8]. In mouse models
of M. avium infection, susceptibility to infection correlated
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Figure 2: Box-and-whisker plots including individual points for the comparison of 109 TB or non-TB specimens showing the optical density
(OD) values of the following selected antigens: anti-NarL IgA (a), anti-19 kDa IgA (b), anti-PstS3 IgA (c), anti-MPT83 IgA (d), anti-AlaDH
IgG (e), and anti-AlaDH IgA (f). Values are shown for sera from 14 healthy controls (HC), 42 TB patients, and 3 different LTBI groups. The
mean ranks of IgA signals against the 5 antigens investigated were used to group the LTBI group into the top 3 group [LTBI (high IgA);
comprising the progressor to active TB disease], the following 16 mean ranks [LTBI (medium IgA)] and the remaining LTBI group [LTBI
(low IgA)]. The symbol ∗ depicted above either the TB patients or the LTBI (high and medium IgA) group shows a significant difference
of this group compared to healthy controls. A 𝑃 value of ≤ 0.05 was judged significant and levels of significance were indicated as follows:
∗
𝑃 = 0.01–0.05, ∗∗𝑃 = 0.001–0.01, ∗∗∗𝑃 < 0.001.
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Table 2: Specificities and sensitivities of single seroantigens to distinguish between healthy non-TB infected controls [HC (𝑛 = 14)] and either
active TB patients (𝑛 = 42) or LTBI [with medium or high IgA levels (𝑛 = 19)].
Antigen Ig class
TB versus HC LTBI (elevated IgA) versus HC
Sens. (%) (95% CI) based
on 92.9% (95% CI,
66.1–99.8%) spec.
Sens. (%) (95% CI) based
on 100% (95% CI,
76.8–100%) spec.
Sens. (%) (95% CI) based
on 92.9% (95% CI,
66.1–99.8%) spec.
Sens. (%) (95% CI) based
on 100% (95% CI,
76.8–100%) spec.
NarL A 81.0 (65.9–91.4)∗∗∗ 78.6 (63.2–89.7)∗∗∗ 84.2 (60.4–96.6)∗∗∗ 84.2 (60.4–96.6)∗∗∗
MPT83 A 47.6 (32.0–63.6)## 2.4 (0.06–12.6)## 63.2 (38.4–83.7)### 0 (0.0–17.6)###
19 kDa A 64.3 (48.0–78.4)∗∗∗ 64.3 (48.0–78.4)∗∗∗ 78.9 (54.4–93.9)∗∗∗ 78.9 (54.4–93.9)∗∗∗
PstS3 A 61.9 (45.6–76.4)∗∗∗ 35.7 (21.6–52.0)∗∗∗ 57.9 (33.5–79.7)∗∗∗ 31.6 (12.6–56.6)∗∗∗
AlaDH G 42.9 (27.7–59.0)∗ 28.6 (15.7–44.6)∗ 26.3 (9.1–51.2) n. s. 15.8 (3.4–39.6) n. s.
AlaDH A 76.2 (60.5–87.9)∗∗∗ 69.0 (52.9–82.4)∗∗∗ 89.5 (66.9–98.7)∗∗∗ 84.2 (60.4–96.6)∗∗∗
Significance levels of 𝑃 values: 𝑃 values refer to the 𝑡-test (if appropriate on log-transformed data) or the Mann-Whitney test where indicated. A 𝑃 value of
≤0.05 was judged significant and levels of significance were indicated as follows: ∗ or #𝑃 = 0.01–0.05, ∗∗ or ##𝑃 = 0.001–0.01, ∗∗∗ or ###𝑃 < 0.001; asterisks refer
to parametric tests, hashes to nonparametric tests.
vs. = versus; n. s. = not significant; sens. = sensitivity; spec. = specificity.
The mean ranks of the IgA signals against the 5 investigated antigens were used to group the LTBI group into the top 19 groups [LTBI with elevated mean IgA
levels (𝑛 = 19)] and the remaining LTBI group [LTBI (low IgA)].
The data were analyzed by using specificity levels of ≥90%, as described by other investigators [36, 37].
Table 3: Spearman correlation between the antibody performances for 53 individuals with LTBIa.
Anti-AlaDH IgG Anti-AlaDH IgA Anti-19 kDa IgA Anti-PstS3 IgA Anti-MPT83 IgA
𝑟 = 0.17 (0.1–0.42)
𝑃 = 0.22
𝑟 = 0.93 (0.87–0.96)
𝑃 < 0.0001
𝑟 = 0.91 (0.85–0.95)
𝑃 < 0.0001
𝑟 = 0.82 (0.71–0.89)
𝑃 < 0.0001
𝑟 = 0.89 (0.81–0.93)
𝑃 < 0.0001 anti-NarL IgA
— 𝑟 = 0.21 (−0.06–0.46)
𝑃 = 0.13
𝑟 = 0.26 (−0.01–0.49)
𝑃 = 0.064
𝑟 = 0.31 (0.04–0.53)
𝑃 = 0.025
𝑟 = 0.27 (0.0–0.50)
𝑃 = 0.052 anti-AlaDH IgG
— — 𝑟 = 0.96 (0.93–0.98)
𝑃 < 0.0001
𝑟 = 0.86 (0.77–0.92)
𝑃 < 0.0001
𝑟 = 0.83 (0.72–0.90)
𝑃 < 0.0001 anti-AlaDH IgA
— — — 𝑟 = 0.88 (0.80–0.93)
𝑃 < 0.0001
𝑟 = 0.83 (0.73–0.90)
𝑃 < 0.0001 anti-19 kDa IgA
— — — — 𝑟 = 0.88 (0.80–0.93)
𝑃 < 0.0001 anti-PstS3 IgA
aSpearman’s coefficient 𝑟 of rank correlation (95% CI for 𝑟).
with increased synthesis of specific anti-bacterial antibodies
[9]. Integration of macaque and human proteome-scale anti-
body profiling data revealed dynamic characteristics of the
antibody response in relation to bacillary burden and infec-
tion outcome [4]. Two individuals with elevated specific IgG
responses originally categorized as LTBI were subsequently
diagnosed to have culture-confirmed active TB within a
few weeks of the serologic testing [6]. Moreover, among
apparently healthy professional contacts of TB patients (or
pathological specimens thereof), elevated specific IgG and/or
IgM responses to mycobacterial antigens were determined in
a subgroup of 9 individuals, of whom 4 (44.4%) developed
active TB within one year after serological testing [5].
Clearly, future large scale, long term prospective studies
in different TB endemic areas are needed to further evaluate
and substantiate the validity of the hypothesis that certain
specific anti-mycobacterial antibody responses are predictors
of future active TB. If true, the reported low specificity of
serodiagnostics for the detection of active TB would turn out
to be due to a high risk for an early stage of progression
to active disease and would then offer new opportunities
to interrupt the cycle of transmission. If our findings are
confirmed the clinical relevance would be as follows: a
corresponding antibody-based test in endemic settingswould
then not differentiate between active TB cases on the one
hand and latent or absent infection on the other hand.
Instead, it would distinguish a high-risk group for preclinical
or active TB from a group that is unlikely to progress to
clinical disease. This would be of particular significance as
such antibody tests could be developed into low-cost, point
of care tests that may be used as screening tools, particularly
in high TB burden low-resource settings. In such a clinical
approach, the pre-screened high risk individuals could then
be investigated using established assays such as X-ray, IGRA,
sputum smear, sputum culture and GeneXpert MTB/RIF for
final clinical assessment [3, 42]. Concerning the serodiag-
nostic results, those LTBI individuals showing the highest
IgA or IgG antibody signals might have the highest risk to
progress to active TB as their higher antibody levels may
indicate higher bacterial loads. The detection of preclinical
and early TB would have considerable clinical impact, as the
identification, close monitoring, or early treatment of those
LTBI with incipient disease would offer an opportunity to
break the cycle of transmission and to prevent more serious
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Figure 3: Correlations of IgA antibody levels in serum of latently M. tuberculosis infected individuals. Scatter graphs showing the relations
between anti-AlaDH IgA and anti-19 kDa IgA (a), anti-NarL IgA and anti-19 kDa IgA (b) and anti-AlaDH IgA and anti-AlaDH IgG (c) as well
as anti-NarL IgA and anti-PstS3 IgA (d) using the optical density (OD) values in diluted sera (𝑛 = 53). The correlation coefficient 𝑟 and the
𝑃 value were calculated using the Spearman rank test. The hexagon with a dot in its center characterizes the progressor to active TB, whereas
all other latentlyM. tuberculosis infected individuals are characterized by the symbol ∇.
lung destruction. In addition, early treatment of LTBI may
decrease the emergence of multidrug resistance- (MDR-)
TB strains [43], as the low numbers and slow turnover of
mycobacteria in LTBI presumably present less opportunity to
develop resistance.
In the present study the LTBI subject with the highest IgA
levels against NarL, AlaDH and 19 kDa developed active TB
within 3 months after recruitment. Although this is in line
with the working hypothesis, one has to be very careful with
its interpretation as we are dealing only with a single case.
Clearly, as stated above, further research is needed to inves-
tigate whether antibody responses to mycobacterial antigens
hold any prognostic significance for subsequent development
of active TB in individuals with LTBI as previously suggested
[4–6, 8].
Though a recent metaanalysis showed that so far neither
IGRAs nor the TST can discriminate the ∼90% of persons
with true LTBI from the ∼10% who will develop active TB
[44], promising tendencies are noteworthy also in this field
[45, 46]. Subjects with high risk for preclinical TB might be
monitored more closely in defined time intervals using the
currently best available resources and should be treatedwhere
applicable.
Due to the low frequency of reactivation in immuno-
competent LTBI individuals even in TB endemic settings,
large-scale longitudinal human studies would have to be
conducted to further investigate whether serologic responses
to mycobacterial antigens hold any prognostic significance
for subsequent development of active TB in individuals with
LTBI (correlates of risk).The results of this study and previous
human and animal studies [4, 5, 7–9, 38–41] suggest that this
is a promising approach, particularly as the serological tests
could be performed on existing stored sera from previous
studies. Our results suggest that for these investigations
besides IgG also IgA serology should be considered. Due
to the important role of IgA antibodies in the lung, the
additional consideration of sputum IgA levels might be
meaningful. The development of point-of-care tests that can
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be used as correlates of risk or as diagnostic for active TB
would constitute a major advance.
5. Conclusions
In conclusion, as suggested in human studies and several
animal models [4, 5, 7–9, 38–41], it remains a promising
hypothesis that those latently infected individuals with anti-
body responses resembling those of active TB subjects are
more prone to progression to active TB. Our finding of a
nonrandom distribution of antibody responses among LTBI
subjects suggests that the development of serodiagnostic kits
for the determination of a high-risk group for preclinical or
active TB in endemic settings may be possible. Furthermore,
our results encourage the further investigation of IgA besides
IgG responses in the field of serodiagnosis of active TB and
possibly preclinical TB. Moreover, IgA antibodies against the
novel antigen NarL were able to determine, besides the puta-
tive high-risk subgroup for preclinical TB (including highest
levels for the actual progressor), the highest proportion of
active TB patients.
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